Analysis identifies distinct glioblastoma subtypes with varied TLS-associated profiles, suggesting implications for immunotherapy.
Motivation: The lack of noninvasive biomarkers to identify tumor subtypes with distinct tertiary lymphoid structure (TLS) -associated transcriptomic profiles hinders the precise prediction of neoadjuvant immunotherapy efficacy in glioblastoma (GBM). Goal(s): To identify glioblastoma subtypes with distinct TLS-associated transcriptomic profiles by habitat-derived radiomics features based on T2-weighted imaging. Approach: Paired analysis of MRI and transcriptomic profiles in GBM patients was conducted to identify tumor subtypes, the radiomics-based model for discirminating subtypes was developed and validated. Results: Two GBM subtypes were identified based on TLS-associated gene characterizations with differential survivals. A habitat-derived radiomics model was developed and validated to classify subtypes with excellent performance. Impact: We developed and validated a classifier based on habitat-derived radiomics features to identify novel GBM subtypes with distinct TLS-associated gene profiles. This may provide a new in vivo approach for precise evaluation of neoadjuvant immunotherapy response in GBM noninvasively.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: